Archive

BTS 2016: Transplantation of kidneys from small paediatric donors. Can we set a limit? Niaz Ahmad, St James’s Hospital, Leeds

by Maria Dalby:  Organ donation from children aged less than 2 years is extremely rare in the UK but could offer significant scope for expanding the donor pool…. read more.

BTS 2016: Transplantation of kidneys from small paediatric donors. Can we set a limit? Niaz Ahmad, St James's Hospital, Leeds

by Maria Dalby:  Organ donation from children aged less than 2 years is extremely rare in the UK but could offer significant scope for expanding the donor pool…. read more.

BTS 2016: Controversies in UK organ transplantation: have we gone too far in terms of organ quantity at the expense of organ quality? Professor Derek Manas (Newcastle upon Tyne) and Lorna Marson (Edinburgh) discuss in this video the plenary on quantity vs quality.

Controversies in UK organ transplantation: have we gone too far in terms of organ quantity at the expense of organ quality? John Forsythe, Edinburgh Royal Infirmary and Chris… read more.

BTS 2016: An interview with Dr Jayme Locke, Transplant Surgery, University of Alabama, Birmingham, AL, USA. The new US kidney allocation scheme.

BTS 2016: Best practice immunosuppression – no more Mr Nice Guy. Interview with Lorna Marson, Lisa Burnapp and Professor Derek Manas from the BTS executive discuss the potential impact on patients if the appeal fails and Professor Nigel Heaton and Dr Varuna Aluvihare (Kings College Hospital) give a surgeon and hepatologist’s view on how NICE renal guidance might affect liver transplantation.

Best practice immunosuppression – no more Mr Nice Guy.   Nicholas Torpey, Addenbrooke’s Hospital, Cambridge. Overview by Maria Dalby The updated recommendations from the National Institute for Health… read more.

BTS 2016: Best practice immunosuppression – no more Mr Nice Guy. Interview with Lorna Marson, Lisa Burnapp and Professor Derek Manas from the BTS executive discuss the potential impact on patients if the appeal fails and Professor Nigel Heaton and Dr Varuna Aluvihare (Kings College Hospital) give a surgeon and hepatologist's view on how NICE renal guidance might affect liver transplantation.

Best practice immunosuppression – no more Mr Nice Guy.   Nicholas Torpey, Addenbrooke’s Hospital, Cambridge. Overview by Maria Dalby The updated recommendations from the National Institute for Health… read more.

BTS 2016: Lorna Marson and Professor John O’Grady discuss proposals for changes to the current kidney and liver allocation schemes in the UK.

Organ Allocation: looking to the future.  An interview with Lorna Marson (University of Edinburgh) and Professor John O’Grady (Kings College Hospital, London)

Meta-analysis suggests need for wider use of blood pressure-lowering drugs

by Bruce Sylvester: No matter what their blood pressure is at the beginning of treatment, blood pressure-lowering drugs should be offered to all persons at high risk of… read more.

Viagra ups insulin sensitivity in prediabetes

by Bruce Sylvester: Treatment with sildenafil, marketed as Viagra and other trade names, appears to improve insulin sensitivity in persons with prediabetes, as well as lowering a biological… read more.

ESOT 2015: Tailored self-management interventions for vulnerable populations

by Maria Dalby: Self-management after undergoing transplantation requires skills and confidence both with respect to taking medications, adhering to medical advice and coping with everyday life.

ESOT 2015: Tailor-made immunosuppression and post-transplant follow-up

by Maria Dalby: Advances in diagnostic techniques, genetic testing and immunosuppressive protocols allow clinicians to tailor interventions to the individual patient’s needs to a greater extent than in… read more.

ESOT 2015: The enemy within: improving adherence. Professor John Forsythe (Edinburgh), Dr Luis Guirado Fundació Puigvert (Barcelona), Lorna Marson (Edinburgh) and Dr Peter Nickerson (Manitoba) discuss the issues around non-adherance in renal transplantation.

Non-adherence with immunosuppressive treatment is potentially one of the most significant risk factors for intra-patient variability (IPV) in drug concentrations – and one that is modifiable. The link… read more.